More than a month after the FDA granted its first approval for an amyotrophic lateral sclerosis (ALS) drug in five years, several promising ALS candidates are winnowing their way through clinical trials—including an oral drug that has shown the first signs of promise in an early-phase study.
Your comment will be posted after it is approved.
Leave a Reply.
Dr. Eric L Reese I
Dr. Eric L. Reese is a 25+ year veteran in the life sciences industry focusing primarily on sales, marketing and business development for startup companies with disruptive technologies. Also, Dr. Reese has authored articles and presented globally on the utility of market-driven applications approaches to sales and marketing for the life sciences market space. To date Dr. Reese has spearheaded over 50+ industry collaborations focused on market development and sales growth utilizing his market-driven applications approach for the life sciences market space.